Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.25 is 34% above its 5-year average of -0.38, near the high end of its 5-year range (-46.77–5.52).
As of the fiscal period ended Tuesday, June 30, 2026. 191.50% below its 12-month average of -0.09.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.25.
DEBT TO EQUITY RATIO
-0.25
DEBT TO EQUITY RATIO AVG TTM
-0.09
DEBT TO EQUITY RATIO AVG 3Y
0.09
DEBT TO EQUITY RATIO AVG 5Y
-0.38
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-191.50%
CURRENT VS 3Y AVG
-384.77%
CURRENT VS 5Y AVG
+33.73%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-328.92%
vs the sector median at left
Ensysce Biosciences, Inc.
Market Cap
$6.64M
Debt to Equity Ratio
-0.25
TTM Avg
-0.09
3Y Avg
0.09
5Y Avg
-0.38
Market Cap
$6.65M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$6.87M
Debt to Equity Ratio
1.71
TTM Avg
0.66
3Y Avg
0.41
5Y Avg
0.34
Market Cap
$6.94M
Debt to Equity Ratio
0.14
TTM Avg
0.05
3Y Avg
0.03
5Y Avg
0.02
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | $6.64M | -0.25 | -0.09 | 0.09 | -0.38 |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.65M | 0.00 | 0.00 | 0.00 | 0.00 |
| Aclarion, Inc. (ACON)vs › | $6.60M | 0.00 | 0.00 | 0.00 | 0.00 |
| Biomerica, Inc. (BMRA)vs › | $6.54M | 0.72 | 0.51 | 0.31 | 0.26 |
| Exicure, Inc. (XCUR)vs › | $6.82M | 0.00 | 0.46 | 0.90 | 0.89 |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.87M | 1.71 | 0.66 | 0.41 | 0.34 |
| Co-Diagnostics, Inc. (CODX)vs › | $6.94M | 0.14 | 0.05 | 0.03 | 0.02 |
| KALA BIO, Inc. (KALA)vs › | $6.96M | 0.00 | 1.31 | 2.43 | 2.58 |
| Femasys Inc. (FEMY)vs › | $6.28M | 1.19 | 2.02 | 1.11 | 0.84 |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.00M | 0.06 | 0.01 | 0.01 | 0.01 |
Debt/Equity
-0.25
Current Ratio
0.70
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.25 |
| 2026-03-31 | -0.72 |
| 2025-12-31 | 0.10 |
| 2025-09-30 | 0.32 |
| 2025-06-30 | 0.13 |
| 2025-03-31 | 0.08 |
| 2024-12-31 | 0.08 |
| 2024-09-30 | 0.06 |
| 2024-06-30 | 0.25 |
| 2024-03-31 | 0.07 |
| 2023-12-31 | -2.65 |
| 2023-09-30 | 0.24 |
| 2023-06-30 | 0.11 |
| 2023-03-31 | 0.11 |
| 2022-12-31 | -1.19 |
| 2022-09-30 | -1.47 |
| 2022-06-30 | -5.43 |
| 2022-03-31 | 5.52 |
| 2021-12-31 | -2.19 |
| 2021-09-30 | -46.77 |
| 2021-06-30 | 0.09 |
| 2021-03-31 | -0.67 |
| 2020-12-31 | -0.66 |
| 2020-09-30 | 0.11 |
| 2020-06-30 | 0.11 |
| 2020-03-31 | 0.16 |
| 2019-12-31 | 0.00 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 18.75 |
